Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

ntial growth in clinical product sales, and demand for certain products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the fact that the audit for 2008 has not yet been completed, and therefore could have audit-related adjustments; the impact of the significant global economic downturn on the company's target markets; success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for MRSA and other Healthcare Associated Infections (HAIs); the company's ability to successfully introduce and sell products in clinical markets other than HAIs; the mix of products sold; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the company's reliance on distributors in some regions to market, sell and support its products; the impact of competitive products and pricing; and the company's ability to manage geographically-dispersed operations. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and its other reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that it will ... operating results on Tuesday, March 10, 2015 after the ... host a conference call and webcast on Tuesday, March ... Pacific to discuss the results and recent corporate developments. ...
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy , ... The GMO TRUTH podcast on both ITunes and at The ... mission to discover the truth and change the world. ... truth about the GMOs in our food supply,” adds a ... an expansion of the documentary/investigative film-making methodology in place at ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... Wis. - Mirus Bio Corp. , a Madison-based ... first outside the U.S., that covers a method of treating ... of genes. , ,The patent, titled "Intravascular Delivery of Nucleic ... therapeutic nucleic acids to body tissues via the blood stream ...
... in an elevator next to a venture capitalist who could ... thing about it yet. , ,You have 90 seconds ... Elevator Pitch Olympics, a yearly event at the Wisconsin ... dished out advice and a few hard knocks to hopeful ...
... and - to paraphrase Sally Field - "You like us, you ... there was a keen observation: that some of the companies debuted ... some of the technologies on the DEMO stage. Yet I suspect ... might argue, does not a company make. Or perhaps I should ...
Cached Biology Technology:Mirus granted European patent for gene therapy 29 tips for making 90 seconds count in an investment pitch 2Sometimes, features can make a company 2Sometimes, features can make a company 3
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... published in the November issue of Nutrition Journal ... may have helped healthy, overweight people feel more satisfied and ... study was funded by the Hass Avocado Board. The ... Effect of Hass Avocado Intake on Post Ingestive Satiety, Glucose ...
... the relative rate of molecular evolution between humans and chimps with ... marches on at a steady pace in all creatures or if ... genetic code occur more rapidly in some groups than in ... Proceedings of the Royal Society B . The team chose ...
... 2014 Despite years of anti-smoking education and legislation, ... in the United States. In 2010, 25.2% of all ... use. While anti-tobacco efforts continue across the county, the ... a less harmful alternative to cigarettes and also as ...
Cached Biology News:New research: Effects of eating half an avocado with lunch on satiety & desire to eat between meals 2Of lice and men (and chimps): Study tracks pace of molecular evolution 2Of lice and men (and chimps): Study tracks pace of molecular evolution 3Perceived benefits of e-cigarettes may lead to higher experimentation rates 2Perceived benefits of e-cigarettes may lead to higher experimentation rates 3
... Workstation is a modular, highly scalable, automated ... 1ml or 3ml industry standard SPE cartridges, ... samples in less than two hours unattended. ... cartridges, and up to 10 modules can ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... evolutionarily conserved form of cell suicide, which ... central component of this process is a ... These enzymes participate in a series of ... pro-apoptotic signals and result in the cleavage ...
... DNA Visualizer Extraction Kit is manufactured ... causing DNA damage byexposure to UV light. ... gel is often used for DNA-cloning work. ... ethidium bromide and exposure of UV light ...
Biology Products: